Bleeding stroke drug shows promise in Fast-Action trial
Disease control
Ongoing
This phase 3 trial tests whether a drug called recombinant factor VIIa (rFVIIa), given within 2 hours of a bleeding stroke, can limit brain damage and improve recovery. About 860 adults aged 18–80 with spontaneous intracerebral hemorrhage are enrolled. The study compares rFVIIa t…
Phase: PHASE3 • Sponsor: Joseph Broderick, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC